TuHURA Biosciences draws $1.5 million more from Parkview credit line

TuHURA Biosciences, Inc. disclosed in an 8-K filed for a September 2, 2026 event that it took a new draw under a revolving credit facility with Parkview Holdings One LLC. On September 2, 2026, the company received and borrowed an additional draw under the revolving credit facility in the amount of $1,500,000 and said it expects to use the funds for general corporate purposes.¹

The credit line itself was set up earlier in the year. TuHURA Biosciences entered into the loan agreement with Parkview Holdings One LLC as lender on April 21, 2026.¹ That agreement established a revolving credit facility maturing April 21, 2031, with total loan availability of up to $50 million.¹

The filing notes that the full terms of the arrangement are set out in the original loan agreement document, which was filed as an exhibit to the company's Form 8-K filed on April 22, 2026.¹

In its forward-looking statements section, TuHURA flagged risks tied to the arrangement, including uncertainty over whether the company can satisfy conditions to draw down funds or stay in compliance with the loan agreement, whether funds available under the facility will be sufficient to cover its operations and development programs as anticipated, and potential conflicts of interest because the lender is affiliated with the company's largest stockholder¹. The company pointed readers to its 10-K for the fiscal year ended December 31, 2025, filed March 31, 2026, and other SEC filings for further risk detail. The 8-K was signed by Chief Financial Officer Dan Dearborn on September 4, 2026.